David Oliver, DO
Family Medicine · Ocala, FLNPI 1164404455
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,489 of the $4,915 with a category attached, or 71.0%. 16 manufacturers reported payments, led by Eli Lilly at 38.7% of the total. Reporting peaked in 2024 at $2,306 and has fallen 84.7% since, to $352 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $83.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Johnson & Johnson$775
- Amgen$574
- Stryker$427
- Bayer$249
- Ironwood Pharmaceuticals, Inc$193
- plus $793 from 10 others
Across 522 payments — averaging $9150.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.6M
- GSK$494K
- Regeneron$224K
- Pfizer$213K
- Novo Nordisk AS$79K
- Tolmar, Inc.$67K
- plus $123K from 5 others
What the payments were for
- Travel & lodging$1,42129%
- Food & beverage$3,48971%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 16 | $1,903 |
| Johnson & Johnson | 8 | $775 |
| Amgen | 11 | $574 |
| Stryker | 3 | $427 |
| Bayer | 2 | $249 |
| Ironwood Pharmaceuticals, Inc | 2 | $193 |
| AbbVie | 2 | $130 |
| Amarin Pharma, Inc. | 2 | $130 |
| Novo Nordisk | 2 | $130 |
| GSK | 1 | $125 |
| Lilly USA, LLC | 3 | $98 |
| Esperion Therapeutics, Inc. | 1 | $71 |
| Philips North America LLC | 2 | $38 |
| Smith+Nephew | 2 | $35 |
| Organogenesis Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,915 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 161 | $185,306 |
| MounjaroTirzepatide | 64 | $89,039 |
| OzempicSemaglutide | 64 | $74,266 |
| EliquisApixaban | 61 | $64,534 |
| FarxigaDapagliflozin Propanediol | 58 | $63,779 |
| XareltoRivaroxaban | 43 | $39,086 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $38,253 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 128 | $28,581 |
| TrulicityDulaglutide | 13 | $28,414 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $27,211 |
| ProliaDenosumab | 11 | $19,819 |
| JanuviaSitagliptin Phosphate | 21 | $16,455 |
| Repatha SureclickEvolocumab | 20 | $15,551 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $10,063 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $8,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $98 | $117,45377 claims |
| Novo NordiskOzempic | $130 | $74,26664 claims |
| GSKShingrix, Trelegy Ellipta, Anoro Ellipta | $125 | $64,123160 claims |
| Johnson & JohnsonXarelto | $775 | $39,08643 claims |
| AmgenProlia | $574 | $19,81911 claims |
| AbbVieSynthroid | $130 | $2,61652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Ocala
- Sidney ClevingerOcala$110K
- Lorn MillerOcala$53K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.